Name (Synonyms) | Correlation | |
---|---|---|
drug730 | NO-Immunosuppressive Wiki | 1.00 |
drug147 | Best Practice Wiki | 1.00 |
drug570 | Immunosuppressive Wiki | 1.00 |
drug1168 | Tocilizumab Wiki | 0.23 |
Name (Synonyms) | Correlation | |
---|---|---|
D007676 | Kidney Failure, Chronic NIH | 0.58 |
D029424 | Pulmonary Disease, Chronic Obstructive NIH | 0.58 |
D003324 | Coronary Artery Disease NIH | 0.58 |
D020521 | Stroke NIH | 0.50 |
D008173 | Lung Diseases, Obstructive NIH | 0.45 |
D009369 | Neoplasms, NIH | 0.30 |
D007239 | Infection NIH | 0.07 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001677 | Coronary artery atherosclerosis HPO | 0.58 |
HP:0006510 | Chronic obstructive pulmonary disease HPO | 0.58 |
HP:0001297 | Stroke HPO | 0.50 |
HP:0006536 | Obstructive lung disease HPO | 0.45 |
HP:0002664 | Neoplasm HPO | 0.30 |
There is one clinical trial.
SAM-COVID is a retrospective cohort study that aims to determine the impact of immunosuppressive drugs and immunoglubulins in the outcome of patients with COVID-19.
Description: Days until invasive mechanical ventilation or death, whatever happened first.
Measure: Invasive ventilation or death Time: Up to 21 daysDescription: Days until mechanical ventilation
Measure: Ventilation Time: Up to 21 daysDescription: Days until death
Measure: Death Time: Up to 21 daysDescription: Proportion of patients developing secondary infections
Measure: Secondary infections Time: Up to 21 daysDescription: Proportion of patients with digestive tract hemorrhage
Measure: Digestive tract hemorrhage Time: Up to 21 daysDescription: Proportion of patients with imnprovement in 2 or more points in 7-point scale by WHO
Measure: Change in 7 points scale Time: Day 21